US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Interim Report Q3 2018

    The win in the patent litigation strengthen Orexo’s long term business opportunities Q3 2018 highlights · Orexo wins appeal against Actavis on Zubsolv patent in the US, expiring in 2032 · Total net revenues of SEK 216.6 million (166.2), up 30.3 percent from Q3 previous year · Zubsolv® US net revenue of SEK 165.4 million (121.1), up 36.6 percent in SEK and 24.3 percent in local currency compared to the same period last year · EBITDA of SEK 39.8 million (46.1), EBITDA excluding IP litigation costs, of SEK 71.0 million (50.8) · US EBIT of SEK 55.6 million (31.8) · Cash

    Orexo appoints Nomination Committee and publishes financial calendar 2018/2019

    Uppsala, Sweden – October 8, 2018 – Prior to the Annual General Meeting 2019, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and votes in the company based on the last known shareholder information. The Nomination Committee, whose tasks include providing proposals to the General Meeting regarding Chairman of the Meeting, Board members, Chairman of the Board, fees for the board members, any remuneration for committee work, proposal for and fees to the company’s auditor as well as principles for composition of the Nomination

    Interim Report Q2 2018

    Zubsolv® continues its strong performance Q2 2018 highlights · Total net revenues of SEK 199.7 million (159.1), up 25.5 percent from Q2 previous year · Zubsolv US net revenue of SEK 158.4 million (124.1), up 27.6 percent in SEK and 29.8 percent in local currency compared to the same period last year · EBITDA of SEK 50.6 million (15.0) · Cash flow from operating activities of SEK 39.0 million (49.0), building a cash balance of SEK 494.8 million (294.3) · Launch of Zubsolv initiated in the EU, which triggered a milestone payment of EUR 3 million · Earnings per share,

    Number of shares and votes in Orexo

    Uppsala, Sweden – June 29, 2018 – The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of 325,000 class C shares as announced on June 15, 2018. Today, the last trading day of the month, there are in total 35,450,456 shares - whereof 34,560,456 are ordinary shares and 890 000 class C shares - and 34,649,456 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and Lena Wange, IR & Communications ManagerCFO                   Tel: +46 (0)18 780 88 Tel: +46 (0)18 780 88 0000E-mail:

    Zubsolv® now launched in the EU, which triggers a EUR 3m milestone payment to Orexo

    Uppsala, Sweden – June 18, 2018 - Orexo AB today announces that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the EU. The launch is triggering a milestone payment ofEUR 3 million (approx. SEK 30.6 million) from Mundipharma. It is estimated that there are approximately 1.3 million high-risk opioid users in Europe. Although estimates vary significantly, the vast majority of high-risk opioid users use heroin. “Taking the step out in Europe, is yet another important milestone

    Issue and repurchase of class C shares

    Uppsala, Sweden – June 15, 2018 – Orexo AB (publ.) announces that the company has resolved to issue and immediately thereafter repurchase 325,000 class C shares. The shares are issued and repurchased in accordance with the long-term incentive program, LTIP 2018, which was adopted by the annual general meeting on April 12, 2018.  Danske Bank subscribes for the entire issue of new class C shares at a subscription price of SEK 0.40 per share, equal to the quota value of the shares. The entire issue of class C shares will thereafter be repurchased by Orexo for SEK 0.40 per share. The

    Orexo´s CFO resigns and will leave the company in November 2018

    Uppsala, Sweden – May 31, 2018 - Orexo AB today announces that Henrik Juuel has notified the company of his resignation after working for five years as the company´s Chief Financial Officer. Henrik Juuel will have his last working day with Orexo in November, before he joins the Danish company Bavarian Nordic A/S as their new CFO. “Henrik was my first new recruitment to the management team of Orexo after I became the CEO in 2013. To convince Henrik to commute from Denmark to Sweden, we agreed on a two-year contract and I am honored Henrik decided to stay with Orexo for an additional three

    Interim Report Q1 2018

    Zubsolv US growth of 26 percent in local currency Q1 2018 highlights · Total net revenues of SEK 139.7 million, up 9.7 percent from Q1 previous year · Zubsolv US net revenue of SEK 131.1 million, up 14.9 percent in SEK and 26.2 percent in local currency compared to the same period last year · EBITDA of SEK -16.6 million, in line with guidance · Cash flow from operating activities of SEK 106.0 million, building a cash balance of SEK 437.5 million · Pipeline update, two more projects disclosed · Earnings per share, before dilution SEK -0.75 (-1.00), earnings per share

    Number of shares and votes in Orexo

    Uppsala, Sweden – January 31, 2018 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 35,125,456 shares, whereof 34,560,456 are ordinary shares and 565,000 class C shares and 34,616,956 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and CFO Lena Wange, IR & Communications ManagerTel: +46 (0)18 780 88 00 Tel: +46 (0)18 780 88 00E-mail: ir@orexo.com E-

    Orexo publishes prospectus and applies for listing of bonds on Nasdaq Stockholm

    Uppsala, Sweden – November 30, 2017 – On 31 October 2017, Orexo AB (publ) (the ”Company”) announced that the Company successfully had issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK 500 million, and a floating interest rate of STIBOR 3m +4.50 per cent per year (quarterly payments in arrears). The Company intends to list the bonds on the corporate bond list of Nasdaq Stockholm. In connection therewith, the Company has prepared a prospectus which has been approved by the Swedish Financial Supervisory Authority. First day for

    Orexo completes early redemption of existing bond loan

    Uppsala, Sweden – November 22, 2017 – Orexo AB (publ.) (the “Company”) today announces that the Company, in accordance with Orexo’s press release on 31 October 2017, has completed the early total redemption of the existing bond loan (ISIN SE0005932159). The redemption was made at an amount corresponding to 101 percent of the nominal amount (i.e. SEK 1,010,000 per bond, the nominal amount being SEK 1,000,000) together with accrued but unpaid interest from the preceding interest payment date on November 9 2017 up to, and including, the redemption date on November 22 2017. In conjunction

    Orexo issues bonds of SEK 325 million and confirms fulfilment of condition under notice of early redemption

    Uppsala, Sweden – October 31, 2017 – Orexo AB (publ.) (the “Company”) has issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK 500 million, due in November 2021. The bond loan has a floating interest rate of STIBOR 3m +4.50 per cent per year (quarterly payments in arrears). The net proceeds from the issue will mainly be used towards prepayment of the Company’s existing outstanding bond loan and for general corporate purposes. The issue date for the new bonds is expected to be 13 November 2017. The Company intends to list the new

    Orexo Interim Report Q3 2017

    Financial overview Q3 2017 · Total net revenues SEK 166.2 million (181.9) · Zubsolv® US net revenue SEK 121.1 million (142.4) · EBIT SEK 40.9 million (43.0) · EBITDA SEK 46.1 million (50.9) · Earnings per share, before and after dilution, SEK 0.82/0.81 (1.04/1.04) · Cash flow from operating activities SEK 92.3 million (31.1) · Cash and cash equivalents SEK 370.7 million (276.9) · Guidance of full year 2017 positive EBITDA is confirmed Financial overview YTD 2017 · Total net revenues SEK 452.6 million (521.2) · Zubsolv US net revenue SEK 359.3 million (

    Orexo appoints Nomination Committee and publishes financial calendar 2017/2018

    Uppsala, Sweden – October 3, 2017 – Prior to the Annual General Meeting 2018, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and votes in the company based on the last known shareholder information. The Nomination Committee, whose tasks include providing proposals to the General Meeting regarding Chairman of the Meeting, Board members, Chairman of the Board, fees for the board members, any remuneration for committee work, proposal for and fees to the company’s auditor as well as principles for composition of the Nomination

    Orexo Interim Report Q2 2017

    Financial overview Q2 2017 · Total net revenues SEK 159.1 million (188.2) · Zubsolv® US net revenue SEK 124.1 million (112.8) · EBIT SEK 9.8 million (12.1) · EBITDA SEK 15.0 million (17.2) · Earnings per share, before and after dilution, SEK 0.09/0.09 (0.14/0.14) · Cash flow from operating activities SEK 48.7 million (20.0) · Cash and cash equivalents SEK 294.3 million (252.9) · Guidance of full year 2017 positive EBITDA is confirmed Other highlights Q2 2017 · Orexo´s partner AstraZeneca advanced OX-CLI into clinical trials which triggered a milestone

    Number of shares and votes in Orexo

    Uppsala, Sweden – June 30, 2017 – The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of class C shares as announced on June 16, 2017. Today, the last trading day of the month, there are in total 35 104 585 shares - whereof 34,539,585 are ordinary shares and 565 000 class C shares - and 34 596 085 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and CFO Lena Wange, IR & Communications ManagerTel: +46 (0)18 780 88 00 Tel: +46 (0)18 780 88 00E-mail: ir@orexo.com E-mail:

    Interim Report Q1 2017

    Financial overview Q1 2017 · Total net revenues SEK 127.4 million (151.0) · Zubsolv® net revenue SEK 114.1 million (98.4) · EBIT SEK -23.2 million (-26.2) · EBITDA SEK -18.1 million (-19.4) · Earnings per share, before and after dilution, SEK -1.00/-1.00 (-1.00/-1.00) · Cash flow from operating activities SEK 28.2 million (33.5) · Cash and cash equivalents SEK 250.6 million (233.0) · Guidance issued in connection with Full Year Report 2016 confirmed Other highlights Q1 2017 · Completion of another bond buyback program amounting to a nominal value of SEK 59

    Orexo commences patent infringement litigation against Actavis for their generic versions of Suboxone® and Subutex® tablets in the US

    Uppsala, Sweden – March 1, 2017 – Orexo AB (publ.) today announced that it has filed a patent infringement action in United States District Court for the District of Delaware against Actavis Elizabeth LLC, Actavis Pharma, Inc., and their parent company Teva (collectively “Actavis”). Orexo alleges that Actavis’s generic versions of Suboxone and Subutex tablets infringe Orexo’s US Patent No. 8,454,996 (the ‘996 patent). On November 15, 2016, the Delaware District Court held Orexo’s ’996 patent (which expires in September 2019) valid and infringed by Actavis’s generic versions of Zubsolv®.

    Orexo Completes Bond Buyback Program

    Uppsala, Sweden – February 20, 2017 – Orexo AB (publ.) announces that it has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 59. The program was initiated on February 8, 2017, and completed by February 17, 2017. After the purchase Orexo owns own bonds with a nominal value of MSEK 158. Pareto Securities and Danske Bank assisted Orexo in this process. For more information please contact: Orexo AB (publ.)Henrik Juuel, EVP and CFO Lena Wange, IR & Communications ManagerTel: +46 (0)18 780

    Full Year Report 2016

    2016 - First profitable year Fourth quarter 2016 · Total net revenues MSEK 184.7 (228.3)   · Zubsolv® net revenue MSEK 128.2 (120.3) · Net earnings MSEK 33.3 (-51.8)  · Earnings per share, before and after dilution, SEK 0.97/0.96 (-1.50) · Cash and cash equivalents MSEK 282.4 (198.1)  · Together with Mundipharma Orexo made the first EU regulatory submission of a Marketing Authorisation Application (MAA) for Zubsolv for the treatment of opioid dependence · FDA approved a new unique low 0.7mg/0.18mg dosage of Zubsolv · The US District Court for the District of

    Orexo Completes Bond Buyback Program

    Uppsala, Sweden – December 21, 2016 – Orexo AB (publ.) announces that it has successfully completed a bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 99. The program was initiated on December 13, 2016, and completed by December 20, 2016. After the purchase the new bond balance is MSEK 401.  Pareto Securities and Danske Bank assisted Orexo in this process. For more information please contact: Orexo AB (publ.)Henrik Juuel, EVP and CFO Lena Wange, IR &

    Orexo appeal Zubsolv® US district court decision

    Uppsala, Sweden, December 8, 2016 - Orexo AB (publ.) announces that it has appealed the decision rendered by the United States District Court for the District of Delaware on November 15, 2016 regarding the validity of Orexo’s US Patent No. 8,940,330 protecting Zubsolv. The decision was rendered in the patent litigation regarding Actavis’s generic Zubsolv 1.4/0.36 mg and 5.7/1.4 mg buprenorphine/naloxone products, and Orexo’s US Patent Nos. 8,454,996 (expiring in September 2019) and 8,940,330 (expiring in September 2032). In the decision, the district court held that Orexo’s ‘996 patent

    Number of shares and votes in Orexo

    Uppsala, Sweden – October 31, 2016 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs and, as previous announced, by issue and repurchase of class C shares. Today, the last trading day of the month, there are in total 34,870,326 shares - whereof 34,535,326 are ordinary shares and 335,000 class C shares - and 34,568,826 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and CFO Lena Wange, IR   & Communications ManagerTel: 018 780

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media